(Q37922644)

25 August 2017

Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis (English)

1 reference

25 August 2017

0 references

Rachel Halpern

1

1 reference

25 August 2017

Sonalee Agarwal

2

1 reference

25 August 2017

Leigh Borton

3

1 reference

25 August 2017

Kathy Oneacre

4

1 reference

25 August 2017

Maria V Lopez-Bresnahan

5

1 reference

25 August 2017

language of work or name

English

0 references

publication date

24 August 2011

1 reference

25 August 2017

1 reference

25 August 2017

28

1 reference

25 August 2017

761-775

1 reference

25 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-011-0054-9

25 August 2017

0 references

cites work

Freedom from disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Medication compliance and persistence: terminology and definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Factors that influence adherence with disease-modifying therapy in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Persistence and adherence to disease modifying drugs among patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Current evidence and therapeutic strategies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Maximising therapeutic outcomes in patients failing on current therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Switching multiple sclerosis patients with breakthrough disease to second-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Methods for evaluation of medication adherence and persistence using automated databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Three years of experience: the Italian registry and safety data update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0054-9

10.1007/S12325-011-0054-9

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference